[1] Tanaka A. Autoimmune Hepatitis: 2019 Update. Gut Liver, 2020, 14: 430-438.
[2] Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis. Nat Rev Dis Primers, 2018, 4: 18017.
[3] Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology, 2010, 51: 2193-2213.
[4] Webb GJ, Hirschfield GM, Krawitt EL, et al. Cellular and Molecular Mechanisms of Autoimmune Hepatitis. Annu Rev Pathol, 2018, 13: 247-292.
[5] Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology, 2010, 139: 58-72.
[6] Nunes MEG, Rosa DV, Fagundes EDT, et al. HLA-DRB1 gene polymorphisms in pediatric patients with type 1 autoimmune hepatitis and type 1 autoimmune hepatitis overlap syndrome with autoimmune cholangitis. Arq Gastroenterol, 2019, 56: 146-150.
[7] Agarwal K, Czaja AJ, Jones DE, et al. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology, 2000, 31: 49-53.
[8] Herkel J. Regulatory T Cells in Hepatic Immune Tolerance and Autoimmune Liver Diseases. Dig Dis, 2015, 33: 70-74.
[9] Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell, 2010, 140: 845-858.
[10] Beringer A, Miossec P. IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases. Autoimmun Rev, 2018, 17: 1176-1185.
[11] Liu Y, Yan W, Yuan W, et al. Treg/Th17 imbalance is associated with poor autoimmune hepatitis prognosis. Clin Immunol, 2019, 198: 79-88.
[12] 张磊, 董砚虎.维生素D抗感染机制研究进展.中华内分泌代谢杂志, 2021, 37: 168-171.
[13] Thiele GM, Duryee MJ, Willis MS, et al. Autoimmune hepatitis induced by syngeneic liver cytosolic proteins biotransformed by alcohol metabolites. Alcohol Clin Exp Res, 2010, 34: 2126-2136.
[14] Czaja AJ, Montano-Loza AJ. Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis. Dig Dis Sci, 2019, 64: 324-344.
[15] Sucher E, Sucher R, Gradistanac T, et al. Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies. J Immunol Res, 2019, 2019: 9437043.
[16] Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol, 2008, 14: 3306-3312.
[17] Holdener M, Hintermann E, Bayer M, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med, 2008, 205: 1409-1422.
[18] Wei Y, Li Y, Yan L, et al. Alterations of gut microbiome in autoimmune hepatitis. Gut, 2020, 69: 569-577.
[19] Manfredo VS, Hiltensperger M, Kumar V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science, 2018, 359: 1156-1161.
[20] Yuksel M, Wang Y, Tai N, et al. A novel "humanized mouse" model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology, 2015, 62: 1536-1550.
[21] Zahs A, Cook RT, Waldschimdt TJ, et al. Alcohol and inflammation and infection: clinical and experimental systems--summary of the 2010 Alcohol and Immunology Research Interest Group Meeting. Alcohol, 2012, 46: 147-153.
[22] Castiella A, Zapata E, Lucena MI, et al. Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World J Hepatol, 2014, 6: 160-168.
[23] Bogdanos DP, Dalekos GN. Enzymes as target antigens of liver-specific autoimmunity: the case of cytochromes P450s. Curr Med Chem, 2008, 15: 2285-2292.
[24] 段金楠, 蔡群, 王浩, 等.维生素D在自身免疫性肝病中的研究进展.中国微生态学杂志, 2021, 33: 614-617.
[25] Almeida MLLK, Lima LA, Alexandre DAPE, et al. Vitamin D (VD3) antioxidative and anti-inflammatory activities: Peripheral and central effects. Eur J Pharmacol, 2020, 879: 173099.
[26] Udomsinprasert W, Jittikoon J. Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies. Biomed Pharmacother, 2019, 109: 1351-1360.
[27] 自身免疫性肝炎诊断和治疗共识(2015).中华传染病杂志, 2016, 34: 193-208.
[28] Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut Liver, 2016, 10: 177-203.
[29] Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology, 2010, 139: 1198-1206.
[30] Terziroli BB, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments. World J Gastroenterol, 2017, 23: 6030-6048.
[31] Pape S, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. United European Gastroenterol J, 2019, 7: 1156-1163.
[32] Zachou K, Gatselis NK, Arvaniti P, et al. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Aliment Pharmacol Ther, 2016, 43: 1035-1047.
[33] Pape S, Nevens F, Verslype C, et al. Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience. Eur J Gastroenterol Hepatol, 2020, 32: 727-732.
[34] Tanaka A. Emerging novel treatments for autoimmune liver diseases. Hepatol Res, 2019, 49: 489-499. |
